SRC Current Studies Data updated on 20 June 2017
No Study Name/Phase Type Sponsor Population (Gender/Age) Estimated target Screened Enrolled Period
1 HPV vaccine /Phase III HPV vaccine MSD ♀ 9-26 yrs 20 21 20 2010-2018
2 TB-018/Phase III TB Vaccine Aeras/GSK ♂/♀ 18-50 yrs 450 1538 468 2014-2018
3 Menacwy/Phase III Menengococccal vaccine Pfizer ♂/♀ 12-14 M 80 90 86 2014-2019
4 ECHO/Phase III HIV risk with Contraception FHI360/UW ♀ 16-35 yrs 800 1133 651  2015-2018
5 STAND Study/Phase III TB Drug therapy TB alliance ♂/♀ ≥18 yrs 102 45 12 2015 –
6 HVTN 100/Phase I/II HIV Vaccine HVTN ♂/♀ 18-40 yrs 42 127 44 2015 – 2020
7 RSV (Season 1)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 50 51 36 2015 -2017
8 RSV (Season 2)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 150 171 118 2016 -2018
9 HVTN702 HIV Vaccine HVTN ♂/♀ 18-35 yrs 410 177 97 2016 -2020
10 HVTN108  HIV Vaccine HVTN ♂/♀ 18-35 yrs 16 52 10 2017 -2019
11 HDT TB TB Treatment ACT4TB / Aurum ♂/♀ 18-65 yrs 50 26 8 2016 – 2018
12 Oral Candidiasis Oral Candida Treatment Aspen ♂/♀ ≥18 yrs 28 3 2 2016 – 2017